Lantheus (LNTH) The 44th Annual William Blair Growth Stock Conference summary

Company history and leadership

• Over 65 years of experience in radiopharmaceuticals, originating from the Manhattan Project.

• Holds the first nuclear licenses for healthcare use; some products from the 1960s still in use.

• Recognized as a leading radiopharmaceutical-focused organization.

Key products and market position

• PYLARIFY, a PET imaging agent for prostate cancer, is expected to surpass $1 billion in sales in 2024, with mid-20% year-over-year growth and a mid-60% market share.

• DEFINITY, an ultrasound-enhancing agent, generates several hundred million dollars in sales and maintains double-digit growth in its 23rd year.

• PYLARIFY's addressable market is projected to double over five years, reaching over $3 billion by decade's end.

Growth drivers and pipeline

• Near-term growth (2024–2025) driven by PYLARIFY and DEFINITY, with continued market expansion and customer education.

• Mid-term growth includes potential launches of PNT2002 (prostate cancer) and PNT2003 (neuroendocrine tumors), with PNT2002 targeting a $5–$10 billion market.

• MK-6240, a tau imaging agent for Alzheimer's, is in phase II and expected to support future growth as new therapies emerge.